{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:28:40Z","timestamp":1791491320915,"version":"4.3.4"},"reference-count":140,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inflammatory bowel disease (IBD) is an immune disorder of the gastrointestinal tract with a complex aetiopathogenesis, whose development is influenced by many factors. The prevalence of IBD is increasing worldwide, in both industrialized and developing countries, making IBD a global health problem that seriously affects quality of life. In 2019, there were approximately 4.9 million cases of IBD worldwide. Such a large number of patients entails significant healthcare costs. In the treatment of patients with IBD, the current therapeutic target is mucosal healing, as intestinal inflammation often persists despite resolution of abdominal symptoms. Treatment strategies include amino salicylates, corticosteroids, immunosuppressants, and biologic therapies that focus on reducing intestinal mucosal inflammation, inducing and prolonging disease remission, and treating complications. The American College of Gastroenterology (ACG) guidelines also indicate that nutritional therapies may be considered in addition to other therapies. However, current therapeutic approaches are not fully effective and are associated with various limitations, such as drug resistance, variable efficacy, and side effects. As the chronic inflammation that accompanies IBD is characterized by infiltration of a variety of immune cells and increased expression of a number of pro-inflammatory cytokines, including IL-6, TNF-\u03b1, IL-12, IL-23 and IFN-\u03b3, new therapeutic approaches are mainly targeting immune pathways. Interleukins are one of the molecular targets in IBD therapy. Interleukins and related cytokines serve as a means of communication for innate and adaptive immune cells, as well as nonimmune cells and tissues. These cytokines play an important role in the pathogenesis and course of IBD, making them promising targets for current and future therapies. In our work, we review scientific studies published between January 2022 and November 2024 describing the most important interleukins involved in the pathogenesis of IBD. Some of the papers present new data on the precise role that individual interleukins play in IBD. New clinical data have also been provided, particularly on blocking interleukin 23 and interleukin 1beta. In addition, several new approaches to the use of different interleukins in the treatment of IBD have been described in recent years.<\/jats:p>","DOI":"10.3390\/ijms26010121","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T19:33:07Z","timestamp":1735241587000},"page":"121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Key Interleukins in Inflammatory Bowel Disease\u2014A Review of Recent Studies"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-6570","authenticated-orcid":false,"given":"David","family":"Aebisher","sequence":"first","affiliation":[{"name":"Department of Photomedicine and Physical Chemistry, Medical College of The Rzesz\u00f3w University, 35-310 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-5464","authenticated-orcid":false,"given":"Dorota","family":"Bartusik-Aebisher","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and General Chemistry, Medical College of The Rzesz\u00f3w University, 35-310 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Przyg\u00f3rzewska","sequence":"additional","affiliation":[{"name":"English Division Science Club, Medical College of The Rzesz\u00f3w University, 35-310 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ole\u015b","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Batorego 15 Street, 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6962-2655","authenticated-orcid":false,"given":"Pawe\u0142","family":"Wo\u017anicki","sequence":"additional","affiliation":[{"name":"English Division Science Club, Medical College of The Rzesz\u00f3w University, 35-310 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kawczyk-Krupka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Batorego 15 Street, 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gubatan, J., Kulkarni, C.V., Talamantes, S.M., Temby, M., Fardeen, T., and Sinha, S.R. (2023). Dietary Exposures and Interventions in Inflammatory Bowel Disease: Current Evidence and Emerging Concepts. Nutrients, 15.","DOI":"10.3390\/nu15030579"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.3748\/wjg.v28.i30.4053","article-title":"Gut microbiota, inflammatory bowel disease and colorectal cancer","volume":"28","author":"Quaglio","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1007\/s10620-024-08491-w","article-title":"Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study","volume":"69","author":"Alperen","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chu, X., Chen, X., Zhang, H., Wang, Y., Guo, H., Chen, Y., Liu, X., Zhu, Z., He, Y., and Ding, X. (2024). Association of diet and outdoor time with inflammatory bowel disease: A multicenter case-control study using propensity matching analysis in China. Front. Public. Health, 12.","DOI":"10.3389\/fpubh.2024.1368401"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00365521.2021.1999495","article-title":"Occupational physical activity differentially affects the risk for developing later-onset Crohn\u2019s disease and ulcerative colitis among middle-aged and older populations","volume":"57","author":"Furuya","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ueg2.12317","article-title":"Implications of the changing epidemiology of inflammatory bowel disease in a changing world","volume":"10","author":"Agrawal","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1053\/j.gastro.2022.07.062","article-title":"The Rising Burden of Inflammatory Bowel Disease in Denmark Over Two Decades: A Nationwide Cohort Study","volume":"163","author":"Agrawal","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: From 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lv, H., Mu, Y., Zhang, C., Zhao, M., Jiang, P., Xiao, S., Sun, H., Wu, N., Sun, D., and Jin, Y. (2024). Comparative analysis of single-cell transcriptome reveals heterogeneity and commonality in the immune microenvironment of colorectal cancer and inflammatory bowel disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1356075"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, M., Li, X., Zhang, Q., Yang, J., and Liu, G. (2023). Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1103617"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.it.2021.11.002","article-title":"Putative regulation of macrophage-mediated inflammation by catestatin","volume":"43","author":"Muntjewerff","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Randeni, N., Bordiga, M., and Xu, B. (2024). A Comprehensive Review of the Triangular Relationship among Diet-Gut Microbiota-Inflammation. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179366"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/ecco-jcc\/jjad064","article-title":"Transepithelial Barrier Dysfunction Drives Microbiota Dysbiosis to Initiate Epithelial Clock-driven Inflammation","volume":"17","author":"Pai","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sahoo, D.K., Heilmann, R.M., Paital, B., Patel, A., Yadav, V.K., Wong, D., and Jergens, A.E. (2023). Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1217165"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn\u2019s disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"ref_18","first-page":"661","article-title":"Crohn\u2019s Disease: Diagnosis and Management","volume":"98","author":"Veauthier","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/jebm.12626","article-title":"Diagnosis and management of inflammatory bowel disease","volume":"17","author":"Li","year":"2024","journal-title":"J. Evid. Based Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: Management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"ref_22","first-page":"768","article-title":"Treatment Strategies in Inflammatory Bowel Diseases","volume":"120","author":"Stallmach","year":"2023","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wang, S., and Li, J. (2021). Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.765474"},{"key":"ref_24","first-page":"CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cgh.2011.10.043","article-title":"Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis","volume":"10","author":"Ford","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","first-page":"CD003715","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"2016","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","first-page":"500","article-title":"The use of 5-aminosalicylates in Crohn\u2019s disease: A retrospective study using the UK Clinical Practice Research Datalink","volume":"33","author":"Hart","year":"2020","journal-title":"Ann. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"480976","DOI":"10.1155\/S0962935192000243","article-title":"Mechanism of action of 5-arninosalicylic acid","volume":"1","author":"Punchard","year":"1992","journal-title":"Mediat. Inflamm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000354699","article-title":"Risks of Inflammatory Bowel Disease Treatment with Glucocorticosteroids and Aminosalicylates","volume":"31","author":"Curkovic","year":"2013","journal-title":"Dig. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2036.2008.03764.x","article-title":"Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis","volume":"28","author":"Yamamoto","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Kopylov","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/13543784.2019.1597053","article-title":"Expert opinion on interleukin-12\/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease","volume":"28","author":"Wong","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: A single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Saez, A., Herrero-Fernandez, B., Gomez-Bris, R., S\u00e1nchez-Martinez, H., and Gonzalez-Granado, J.M. (2023). Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021526"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: From biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.intimp.2013.08.012","article-title":"A critical role for interleukin-1\u03b2 in the progression of autoimmune diseases","volume":"17","author":"Zhao","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1074\/jbc.M116.723064","article-title":"Structural and Functional Attributes of the Interleukin-36 Receptor","volume":"291","author":"Yi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1053\/j.gastro.2016.08.055","article-title":"Interleukin 1\u03b2 Mediates Intestinal Inflammation in Mice and Patients with Interleukin 10 Receptor Deficiency","volume":"151","author":"Shouval","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Aggeletopoulou, I., Kalafateli, M., Tsounis, E.P., and Triantos, C. (2024). Exploring the role of IL-1\u03b2 in inflammatory bowel disease pathogenesis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1307394"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbrc.2020.04.073","article-title":"Development and application of an antibody that binds to interleukin-1\u03b2 of various mammalian species for the treatment of inflammatory diseases","volume":"527","author":"Oh","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Shaul, E., Conrad, M.A., Dawany, N., Patel, T., Canavan, M.C., Baccarella, A., Weinbrom, S., Aleynick, D., Sullivan, K.E., and Kelsen, J.R. (2022). Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.972114"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.51821\/86.4.11246","article-title":"Successful treatment of ulcerative colitis with anakinra: A case report","volume":"86","author":"Truyens","year":"2023","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1039\/D3MD00451A","article-title":"Discovery of a dual-acting inhibitor of interleukin-1\u03b2 and STATs for the treatment of inflammatory bowel disease","volume":"15","author":"Cai","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_51","first-page":"41","article-title":"Estrogen receptor \u03b2 activation alleviates inflammatory bowel disease by suppressing NLRP3-dependent IL-1\u03b2 production in macrophages via downregulation of intracellular calcium level","volume":"17","author":"Zhu","year":"2024","journal-title":"J. Adv. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102520","DOI":"10.1016\/j.ceca.2021.102520","article-title":"Specific cytokines of interleukin-6 family interact with S100 proteins","volume":"101","author":"Kazakov","year":"2022","journal-title":"Cell Calcium."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-2478(88)90099-5","article-title":"Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2)","volume":"17","author":"Hirano","year":"1988","journal-title":"Immunol. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mi.2008.7","article-title":"New therapeutic strategies for treatment of inflammatory bowel disease","volume":"1","author":"Atreya","year":"2008","journal-title":"Mucosal Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/BF02064182","article-title":"Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent","volume":"40","author":"Kusugami","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Alhendi, A., and Naser, S.A. (2023). The dual role of interleukin-6 in Crohn\u2019s disease pathophysiology. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295230"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.4049\/jimmunol.171.6.3194","article-title":"IL-6 induces NF-kappa B activation in the intestinal epithelia","volume":"171","author":"Wang","year":"2003","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/art.33496","article-title":"Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome","volume":"64","author":"Strippoli","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2017-314562","article-title":"Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn\u2019s disease (ANDANTE I and II)","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gesiorowski, A., Ettich, J., Werner, J., Wittich, C., Pieper, S., Padrini, G., Behnke, K., Floss, D.M., Lang, P.A., and Moll, J.M. (2023). Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12\/23 or tumor necrosis factor (TNF) signaling. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.105343"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Godala, M., Gaszy\u0144ska, E., Walczak, K., and Ma\u0142ecka-Wojciesko, E. (2023). Role of Serum Interleukin-6, Interleukin-1\u03b2 and Interleukin-10 in Assessment of Disease Activity and Nutritional Status in Patients with Inflammatory Bowel Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185956"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s10620-023-07871-y","article-title":"Interleukin-10 Knockout Mice Do Not Reliably Exhibit Macroscopic Inflammation: A Natural History Endoscopic Surveillance Study","volume":"68","author":"Kim","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1084\/jem.170.6.2081","article-title":"Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones","volume":"170","author":"Fiorentino","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","article-title":"The regulation of IL-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"Rennick","year":"1993","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1084\/jem.187.4.571","article-title":"The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Receptor","volume":"187","author":"Spencer","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wei, H.X., Wang, B., and Li, B. (2020). IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01315"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3748\/wjg.v10.i5.620","article-title":"IL-10 and its related cytokines for treatment of inflammatory bowel disease","volume":"10","author":"Li","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa2312302","article-title":"Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease","volume":"391","author":"Griffin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Liu, J., Lai, X., Bao, Y., Xie, W., Li, Z., Chen, J., Li, G., Wang, T., Huang, W., and Ma, Y. (2022). Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.853894"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2119054","DOI":"10.1080\/19490976.2022.2119054","article-title":"Microbiota manipulation to increase macrophage IL-10 improves colitis and limits colitis-associated colorectal cancer","volume":"14","author":"Kim","year":"2022","journal-title":"Gut Microbes."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphs.2021.09.007","article-title":"KCa3.1 inhibition-induced activation of the JNK\/c-Jun signaling pathway enhances IL-10 expression in peripherally-induced regulatory T cells","volume":"148","author":"Matsui","year":"2022","journal-title":"J. Pharmacol. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.4049\/jimmunol.2000848","article-title":"A Novel Fusion of IL-10 Engineered to Traffic across Intestinal Epithelium to Treat Colitis","volume":"205","author":"Fay","year":"2020","journal-title":"J. Immunol."},{"key":"ref_76","unstructured":"Applied Molecular Transport (2024, December 14). A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis (LOMBARD) clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04583358."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ben-Khemis, M., Liu, D., Pintard, C., Song, Z., Hurtado-Nedelec, M., Marie, J.C., El-Benna, J., and Dang, P.M.C. (2023). TNF\u03b1 counteracts interleukin-10 anti-inflammatory pathway through the NOX2-Lyn-SHP-1 axis in human monocytes. Redox Biol., 67.","DOI":"10.1016\/j.redox.2023.102898"},{"key":"ref_78","first-page":"1769290","article-title":"New-Onset Crohn\u2019s Disease following Initiation of Secukinumab: A Case Report and Review of the Role of IL-17 in the Pathogenesis of Crohn\u2019s Disease","volume":"2023","author":"Khouri","year":"2023","journal-title":"Case Rep. Gastrointest. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Menesy, A., Hammad, M., Aref, S., and Abozeid, F.A.M. (2024). Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03218-7"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients with Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/mi.2008.28","article-title":"IL-23 and Th17 cytokines in intestinal homeostasis","volume":"1","author":"Maloy","year":"2008","journal-title":"Mucosal Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Cai, Y., Jia, X., Xu, L., Chen, H., Xie, S., and Cai, J. (2023). Interleukin-17 and inflammatory bowel disease: A 2-sample Mendelian randomization study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1238457"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cao, M., Chen, P., Peng, B., Cheng, Y., Xie, J., Hou, Z., Chen, H., Ye, L., Li, H., and Wang, H. (2023). The transcription factor ELF4 alleviates inflammatory bowel disease by activating IL1RN transcription, suppressing inflammatory TH17 cell activity, and inducing macrophage M2 polarization. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1270411"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chen, J., and Yao, J. (2023). Th22 cells and the intestinal mucosal barrier. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1221068"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"31335","DOI":"10.1074\/jbc.M005304200","article-title":"Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R","volume":"275","author":"Xie","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.164.4.1814","article-title":"Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9","volume":"164","author":"Dumoutier","year":"2000","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41385-022-00506-x","article-title":"TNF hampers intestinal tissue repair in colitis by restricting IL-22 bioavailability","volume":"15","author":"Ninnemann","year":"2022","journal-title":"Mucosal Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1038\/s41467-020-18262-6","article-title":"Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity","volume":"11","author":"Yang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e153488","DOI":"10.1172\/jci.insight.153488","article-title":"KLF5 protects the intestinal epithelium against Th17 immune response in a murine colitis model","volume":"7","author":"Shieh","year":"2022","journal-title":"JCI Insight"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.stem.2022.08.002","article-title":"Optimized human intestinal organoid model reveals interleukin-22-dependency of paneth cell formation","volume":"29","author":"He","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e13363","DOI":"10.1111\/cpr.13363","article-title":"Nestin+ Peyer\u2019s patch resident MSCs enhance healing of inflammatory bowel disease through IL-22-mediated intestinal epithelial repair","volume":"56","author":"Chen","year":"2023","journal-title":"Cell Prolif."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41385-022-00577-w","article-title":"Epithelial dysfunction is prevented by IL-22 treatment in a Citrobacter rodentium-induced colitis model that shares similarities with inflammatory bowel disease","volume":"15","author":"Zhu","year":"2022","journal-title":"Mucosal Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Fantou, A., Lagrue, E., Laurent, T., Delbos, L., Blandin, S., Jarry, A., Beriou, G., Braudeau, C., Salabert, N., and Marin, E. (2022). IL-22BP production is heterogeneously distributed in Crohn\u2019s disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1034570"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Breugelmans, T., Arras, W., Oosterlinck, B., Jauregui-Amezaga, A., Somers, M., Cuypers, B., Laukens, K., De Man, J.G., De Schepper, H.U., and De Winter, B.Y. (2023). IL-22-Activated MUC13 Impacts on Colonic Barrier Function through JAK1\/STAT3, SNAI1\/ZEB1 and ROCK2\/MAPK Signaling. Cells, 12.","DOI":"10.3390\/cells12091224"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"G123","DOI":"10.1152\/ajpgi.00260.2023","article-title":"IL-22 regulates MASTL expression in intestinal epithelial cells","volume":"327","author":"Pravoverov","year":"2024","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12964-024-01846-w","article-title":"Human IL-22 receptor-targeted small protein antagonist suppress murine DSS-induced colitis","volume":"22","author":"Groza","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Tian, Z., Zhao, Q., and Teng, X. (2024). Anti-IL23\/12 agents and JAK inhibitors for inflammatory bowel disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1393463"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Song, Y., Yuan, M., Xu, Y., and Xu, H. (2022). Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091080"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Zurba, Y., Gros, B., and Shehab, M. (2023). Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030747"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kofla-D\u0142ubacz, A., Pytrus, T., Akutko, K., Sputa-Grzegrz\u00f3\u0142ka, P., Piotrowska, A., and Dzi\u0119giel, P. (2022). Etiology of IBD-Is It Still a Mystery?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012445"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"He, R., Zhao, S., Cui, M., Chen, Y., Ma, J., Li, J., and Wang, X. (2023). Cutaneous manifestations of inflammatory bowel disease: Basic characteristics, therapy, and potential pathophysiological associations. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1234535"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Korta, A., Kula, J., and Gomu\u0142ka, K. (2023). The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210172"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"112128","DOI":"10.1016\/j.celrep.2023.112128","article-title":"Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells","volume":"42","author":"Jacobse","year":"2023","journal-title":"Cell Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41586-024-07537-3","article-title":"CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation","volume":"630","author":"Ahmed","year":"2024","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"156743","DOI":"10.1016\/j.cyto.2024.156743","article-title":"Case-control study of IL23R rs76418789 polymorphism, smoking, and ulcerative colitis in Japan","volume":"183","author":"Miyake","year":"2024","journal-title":"Cytokine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.mucimm.2024.05.008","article-title":"IL-23 exerts dominant pathogenic functions in Crohn\u2019s disease-ileitis","volume":"17","author":"Iliopoulou","year":"2024","journal-title":"Mucosal Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e2208160119","DOI":"10.1073\/pnas.2208160119","article-title":"Chronic stress induces colonic tertiary lymphoid organ formation and protection against secondary injury through IL-23\/IL-22 signaling","volume":"119","author":"Gupta","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2967\/jnumed.123.265649","article-title":"Detection of IL12\/23p40 via PET Visualizes Inflammatory Bowel Disease","volume":"64","author":"Rezazadeh","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"67","author":"Honap","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ibd\/izad073","article-title":"Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn\u2019s Disease: An Experience of 2 IBD Centers","volume":"30","author":"McDonald","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1093\/ibd\/izae133","article-title":"Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients with Crohn\u2019s Disease: A Prospective Pilot Study","volume":"30","author":"Bertani","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Sands, B.E., D\u2019Haens, G., Clemow, D.B., Irving, P.M., Johns, J.T., Gibble, T.H., Abreu, M.T., Lee, S.D., Hisamatsu, T., and Kobayashi, T. (2024). Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm. Bowel Dis., izae253.","DOI":"10.1093\/ibd\/izae253"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving Histological Inflammation in Ulcerative Colitis with Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes","volume":"17","author":"Magro","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5217\/ir.2023.00043","article-title":"Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: A subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies","volume":"22","author":"Kobayashi","year":"2024","journal-title":"Intest. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/ibd\/izae004","article-title":"Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials","volume":"30","author":"Higgins","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.14309\/ctg.0000000000000578","article-title":"Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study","volume":"14","author":"Steere","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn\u2019s Disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ecco-jcc\/jjad168","article-title":"Maintenance Risankizumab Sustains Induction Response in Patients with Crohn\u2019s Disease in a Randomized Phase 3 Trial","volume":"18","author":"Ferrante","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ibd\/izac246","article-title":"The Clinical Response of Upadacitinib and Risankizumab Is Associated with Reduced Inflammatory Bowel Disease Anti-TNF-\u03b1 Inadequate Response Mechanisms","volume":"29","author":"Wang","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Danese, S., Beaton, A., Duncan, E.A., Mercier, A.K., Neisen, J., Seth, H., Zetterstrand, S., and Sands, B.E. (2023). Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn\u2019s disease. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-03078-7"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e1636","DOI":"10.1002\/ctm2.1636","article-title":"Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-\u03b1 and IL-23p19 bioactivities","volume":"14","author":"Wang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Cui, Y., David, M., Bouchareychas, L., Rouquier, S., Sajuthi, S., Ayrault, M., Navarin, C., Lara, G., Lafon, A., and Saviane, G. (2024). IL23R-specific CAR Tregs for the treatment of Crohn\u2019s disease. J. Crohns Colitis., jjae135.","DOI":"10.1093\/ecco-jcc\/jjae135"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"121868","DOI":"10.1016\/j.lfs.2023.121868","article-title":"IL-33\u2019s role in the gut immune system: A comprehensive review of its crosstalk and regulation","volume":"327","author":"Kaur","year":"2023","journal-title":"Life Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5009\/gnl220045","article-title":"Cellular and Molecular Mechanisms of Intestinal Fibrosis","volume":"17","author":"Wu","year":"2023","journal-title":"Gut Liver"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ibd.21175","article-title":"Characterization of the novel ST2\/IL-33 system in patients with inflammatory bowel disease","volume":"16","author":"Farfan","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Griesenauer, B., and Paczesny, S. (2017). The ST2\/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00475"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Williams, M.A., O\u2019Callaghan, A., and Corr, S.C. (2019). IL-33 and IL-18 in Inflammatory Bowel Disease Etiology and Microbial Interactions. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01091"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"156015","DOI":"10.1016\/j.cyto.2022.156015","article-title":"IL-33\/ST2 axis in autoimmune disease","volume":"158","author":"Shakerian","year":"2022","journal-title":"Cytokine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00535-010-0245-1","article-title":"Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis","volume":"45","author":"Kobori","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Toskas, A., Milias, S., Delis, G., Meditskou, S., Sioga, A., and Papamitsou, T. (2023). Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132185"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/1\/121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:00:49Z","timestamp":1760115649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/1\/121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":140,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26010121"],"URL":"https:\/\/doi.org\/10.3390\/ijms26010121","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}